DAWN — Day One Biopharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.08bn
- $624.46m
- $131.16m
- 70
- 20
- 84
- 60
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.39 | ||
| Price to Tang. Book | 2.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.22% | ||
| Return on Equity | -30.16% | ||
| Operating Margin | -123.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 131.16 | 152.08 | 225.91 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
Directors
- Julie Grant CHM (38)
- Jeremy Bender PRE (49)
- Samuel Blackman CFD (52)
- Charles York CFO (44)
- Mike Preigh CTO
- Lisa Bowers OTH
- Natalie Holles LED (48)
- Scott Garland DRC (53)
- Dan Becker IND (45)
- Derek Di Rocco IND (41)
- Michael Gladstone IND (34)
- John Josey IND (60)
- Saira Ramasastry IND (45)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- November 1st, 2018
- Public Since
- May 27th, 2021
- No. of Shareholders
- 32
- No. of Employees
- 184
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 102,675,502
- Address
- 1800 Sierra Point Parkway, Suite 200, BRISBANE, 94005
- Web
- https://dayonebio.com/
- Phone
- +1 6504840899
- Auditors
- Ernst & Young LLP
Upcoming Events for DAWN
Day One Biopharmaceuticals Inc Annual Shareholders Meeting
Q2 2026 Day One Biopharmaceuticals Inc Earnings Release
Similar to DAWN
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Day One Biopharmaceuticals share price?
As of Today at 01:12 UTC, shares in Day One Biopharmaceuticals are trading at $10.48. This share price information is delayed by 15 minutes.
How has the Day One Biopharmaceuticals share price performed this year?
Shares in Day One Biopharmaceuticals last closed at $10.48 and the price had moved by -14.24% over the past 365 days. In terms of relative price strength the Day One Biopharmaceuticals share price has underperformed the S&P500 Index by -23.26% over the past year.
What are the analyst and broker recommendations for Day One Biopharmaceuticals?
The overall consensus recommendation for Day One Biopharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Day One Biopharmaceuticals dividend yield?
Day One Biopharmaceuticals does not currently pay a dividend.
Does Day One Biopharmaceuticals pay a dividend?
Day One Biopharmaceuticals does not currently pay a dividend.
When does Day One Biopharmaceuticals next pay dividends?
Day One Biopharmaceuticals does not currently pay a dividend.
How do I buy Day One Biopharmaceuticals shares?
To buy shares in Day One Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Day One Biopharmaceuticals?
As of the previous close price of $10.48, shares in Day One Biopharmaceuticals had a market capitalisation of $1.08bn.
Where are Day One Biopharmaceuticals shares listed?
Here are the trading details for Day One Biopharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DAWN
What kind of share is Day One Biopharmaceuticals?
Based on an overall assessment of its quality, value and momentum Day One Biopharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Day One Biopharmaceuticals share price forecast for 2026?
The analyst consensus target price for shares in Day One Biopharmaceuticals is $22.67. That is 116.32% above the last closing price of $10.48.
Analysts covering Day One Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.99 for the next financial year.
Find out moreWhat is the trend in the Day One Biopharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Day One Biopharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +61.06%.
As of the last closing price of $10.48, shares in Day One Biopharmaceuticals were trading +34.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Day One Biopharmaceuticals PE Ratio?
The Day One Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Day One Biopharmaceuticals?
Day One Biopharmaceuticals' management team is headed by:
- Julie Grant - CHM
- Jeremy Bender - PRE
- Samuel Blackman - CFD
- Charles York - CFO
- Mike Preigh - CTO
- Lisa Bowers - OTH
- Natalie Holles - LED
- Scott Garland - DRC
- Dan Becker - IND
- Derek Di Rocco - IND
- Michael Gladstone - IND
- John Josey - IND
- Saira Ramasastry - IND